Petrucci, Luigi
 Distribuzione geografica
Continente #
NA - Nord America 815
EU - Europa 212
AS - Asia 64
AF - Africa 20
SA - Sud America 1
Totale 1112
Nazione #
US - Stati Uniti d'America 799
IT - Italia 104
SE - Svezia 51
IN - India 39
CN - Cina 20
TG - Togo 20
CA - Canada 16
FR - Francia 11
FI - Finlandia 10
UA - Ucraina 10
DE - Germania 9
RO - Romania 5
NL - Olanda 4
BG - Bulgaria 3
BE - Belgio 2
IE - Irlanda 2
TR - Turchia 2
AR - Argentina 1
GB - Regno Unito 1
HK - Hong Kong 1
ID - Indonesia 1
MY - Malesia 1
Totale 1112
Città #
Fairfield 160
Chandler 70
Seattle 65
Houston 61
Woodbridge 61
Cambridge 53
Wilmington 48
Ashburn 46
Ann Arbor 44
San Paolo di Civitate 36
Rome 32
Princeton 28
Lawrence 21
Millbury 21
Lomé 20
Beijing 16
San Diego 14
Plano 12
Andover 11
Boston 10
Bremen 8
Vancouver 7
Squamish 6
Bologna 5
Norwalk 5
San Mateo 5
Trento 5
Des Moines 4
Redwood City 3
Sofia 3
Trumbull 3
Brussels 2
Dearborn 2
Fremont 2
Istanbul 2
Jacksonville 2
Menlo Park 2
Toronto 2
Absecon 1
Boardman 1
Buffalo 1
Cagnes-sur-mer 1
Federal 1
Hefei 1
Indiana 1
Jakarta 1
Kunming 1
Leawood 1
Mcallen 1
Montecalvoli 1
Montreal 1
Nutley 1
Saint Etienne 1
Southend 1
Tenhult 1
Tivoli 1
Totale 915
Nome #
EFFICACY, SAFETY AND COST ANALYSIS OF SUBCUTANEOUS VS INTRAVENOUS RITUXIMAB IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH RCHOP 82
Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib. 80
Combination of azacitidine and ESA in myelodysplastic patients: The need for prospective studies 66
5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. 66
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma. a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI) 64
Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase. 64
A prospective unicentric survey on donor-specific antibodies DSA and desensitization strategy 62
Neutropenia at baseline could indicate poor prognosis in low/intermediate risk myelodysplastic syndrome patients 56
Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders 52
null 51
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. 48
Evaluation of prognostic factors for overall survival in patients with chronic myelomonocytic leukemia by different scoring systems: which is the best? 43
Human herpesvirus-8–positive primary effusion lymphoma in HIV-negative patients: single institution case series with a multidisciplinary characterization 43
Management of elderly and unfit patients with chronic lymphocytic leukemia 43
Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy 42
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy 40
Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response 37
COVID-19 in patients with hematologic disorders undergoing therapy: perspective of a large referral hematology center in Rome 36
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 35
PREDICTIVE FACTORS FOR INFECTIOUS ADVERSE EVENTS IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA TREATED WITH BENDAMUSTINE-RITUXIMAB (R)+/- R MAINTENANCE. RESULTS OF A RETROSPECTIVE ANALYSIS 31
LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN COMPLETE MOLECULAR RESPONSE WITH ALPHA-INTERFERON AFTER TREATMENT DISCONTINUATION 27
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 25
A prognostic model for patients with lymphoma and COVID-19. a multicentre cohort study 24
Prognostic Features of Myelodysplastic Syndrome Patients Aged < 50 years: Update of a Single Institution Experience. 23
Bing-Neel syndrome coexisting with oligodendroglioma 17
Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL) 14
Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia 5
Donor cell derived mantle cell lymphoma in a HSCT sibling donor-recipient pair: intrinsic biological clock in lymphomagenesis 3
Totale 1179
Categoria #
all - tutte 1764
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1764


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20187 0000 00 06 1000
2018/201990 0310 04 00 0163927
2019/2020240 2812412 2522 3629 26221311
2020/2021213 109116 1978 811 9221416
2021/2022318 592627 3420 335 24304362
2022/2023278 55952421 3436 130 0000
Totale 1179